Publication [Download PDF]: MicroRNA29a regulates the expression of the nuclear oncogene Ski. Blood. 118(7):1899-902. doi: 10.1182/blood-2010-09-306258
Acute myeloid leukemia (AML) is a rapidly progressing cancer characterized by the abnormal buildup of myeloid cells that interfere with normal blood cell (red, white and platelet) function. There are certain genetic markers, for example monosomy 7 (–7) and 7q deletion (del7q), that are correlated with particularly poor prognosis. Ski is a nucleoprotein, homologous to the v-SKI oncogene of the avian leukosis retrovirus, and upregulated in AML patients, even more so in those with -7/del7q mutations. Because miRNAs are known to affect gene expression via both posttransctiptional and translational means, Teichler et al. (Myeloid Neoplasia, 2019) investigated whether a miRNA could be contributing to AML. miRNAs are known to regulate various cell processes such as differentiation, proliferation and apoptosis; aberrant microRNA expression has been correlated to various leukemias.
With services provided by Altogen Labs, Teichler et al. identified microRNA29a as a regulator of Ski. miR-29a was shown to localize on chromosome 7q, be down-regulated in AML, and be inversely correlated to Ski expression. Overall this data suggests that miR-29a effectively functions as a tumor-suppressor by deregulating epigenetic control in leukemogenic gene expression. Methods for obtaining these results include an oligonucleotide array for identification of miRNA expression patterns, a luciferase assay for the validation of binding sites, western blotting for detection of Ski, proliferation and differentiation assays for analysis of exogenously induced miR-29a expression and flow cytometry for measuring Ski.
Altogen Labs is a biology and biotechnology contract research company offering a wide range of services such as those outlined above. We have a team of practiced scientists available to help in every step of the research process from experiment design and carrying out experiments and assays to data analysis. Popular assays include compound characterization, IC50 evaluations and toxicity screening for both in vitro and in vivo assays with a selection of over 100 cell models. Altogen Labs offers highly competitive pricing tailored to client needs to deliver efficient, quality results.